Shares of Vaxart, Inc. (VXRT) are climbing more than 3% Wednesday morning after the clinical-stage biotechnology company signed a license agreement with Altesa Biosciences, Inc. for Vaxart's investigational antiviral drug Vapendavir.
As per the agreement, Altesa gets global rights to develop and commercialize Vapendavir.
Vaxart will receive up to $130 million in milestone payments, and royalties ranging from low-single to low-double digits on global product sales of Vapendavir.
Vapendavir has showed activity against a range of infections including epidemic hand, foot and mouth disease, HRV infection in chronic obstructive pulmonary disease, among others.
VXRT is at $7.61 currently. It has traded in the range of $3.50- $24.90 in the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.